Loading stock data…
Veradermics, Incorporated (MANE)
$103.83+5.32 (+5.40%)
Market ClosedLast close Sep 8
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | — | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.71M↓ | -$22.75M | — | -$12.88M↓ | -$5.58M |
| Net Income | -$27.23M↓ | -$21.85M | — | -$12.40M↓ | -$5.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.19%
Volume
Today's trading volume
711,925
Recent News
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Veradermics has delivered a very strong year-to-date share price gain, yet the valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up 160.8% year to date, which means anyone buying now is stepping in after a very sharp re-rating. Future valuation for Veradermics can hinge on how effectively the company converts its growth opportunities into durable cash flow, while any stumble on execution or profitability could...
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
Veradermics (MANE) drew investor attention after recent trading data highlighted a year to date return above 160%, a market value of about US$4.1b and a last close of US$98.46. Over the shorter term, Veradermics has given back some ground, with the 7 day share price return down 4.22% and the 30 day share price return down 3.37%. However, the year to date share price return of 160.82% suggests momentum has still been strong overall. Compare the surge in Veradermics with a curated group of...
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.
Veradermics (MANE) Positioned to Disrupt Hair Loss Market
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics Incorporated on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. The company said the treatment produced consistent hair growth, demonstrated an early onset of activity, and...